Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why

We recently published 10 Big Names Crushing the Market. Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the best-performing stocks on Friday.

Adaptive Biotechnologies soared to a new three-year high on Friday, as investors resorted to bargain-hunting after the stock fell back to the $13 level earlier in the week.

At intra-day trading, the stock climbed to its highest price of $18.98 before trimming a few cents to end the day just up by 14.03 percent at $18.61 apiece.

Additionally, investors loaded portfolios following the recently concluded Jefferies London Healthcare Conference 2025, where it announced its operational updates and outlook for the full year.

Among others, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) said it expects its pharmaceutical services to generate $20 million in revenues, and anticipates EMR integrated testing volumes to exceed 50 percent by year-end.

Meanwhile, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is also set to participate in the upcoming Piper Sandler Healthcare Conference on December 3.

In the third quarter of the year, Adaptive Biotechnologies Corporation (NASDAQ:ADPT) swung to an attributable net income of $9.5 million from a $32.07 million net loss in the same period last year.

Revenues expanded by 102 percent to $93.97 million from $46.4 million year-on-year, including $33.7 million of revenues from Immune Medicine recognized upon the full amortization of payments previously received under the Genentech Agreement, which was terminated in August 2025.

While we acknowledge the potential of ADPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.